GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLAUKOS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$166.96+2.12 (+1.29%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
GLAUKOS Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | $155.18M | $129.26M | $119.15M | $110.25M | $103.53M | $88.14M | $84.14M | $76.03M | $75.88M | $67.22M | $60.57M | $58.34M | 83.6% | +49.9% |
| Corneal Health | $30.43M | $21.31M | $23.97M | $23.29M | $20.59M | $18.53M | $21.36M | $20.64M | $19.81M | $18.40M | $21.79M | $19.71M | 16.4% | +47.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $146.74M | $112.34M | $108.00M | $101.45M | $90.52M | $75.07M | $75.57M | $70.02M | $66.82M | $57.69M | $58.40M | $55.40M | 79.1% | +62.1% |
| International | $38.87M | $38.23M | $35.12M | $32.09M | $33.60M | $31.59M | $29.93M | $26.65M | $28.87M | $27.93M | $23.96M | $22.65M | 20.9% | +15.7% |
From the segment and revenue-disaggregation notes of Glaukos's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.